Skip to content
Study details
Enrolling now

Cancer Treatment Informed by the Molecular Tumor Board At Dartmouth

Dartmouth-Hitchcock Medical Center
NCT IDNCT05405413ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

192

Study length

about 5.8 years

Ages

18+

Locations

1 site in NH

What this study is about

Researchers are testing whether treatment recommendations from a Molecular Tumor Board impact how doctors make decisions about cancer treatment at Dartmouth Cancer Center. The trial will involve patients whose tumors are genetically profiled and who meet specific eligibility criteria. Doctors will be asked to complete surveys about how the Molecular Tumor Board's evaluation influenced their treatment choices.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Treatment recommendations made by Molecular Tumor Board

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: Number of participants with progression-free survival after Molecular Tumor Board recommendations were made., Time to treatment failure

Body systems

Oncology